Merck withdraws cholesterol drug Tredaptive globally

WHITEHOUSE STATION, N.J., Fri Jan 11, 2013 — Merck & Co. Inc. said it would withdraw its cholesterol drug Tredaptive from markets worldwide after European regulators recommended that marketing of the drug be suspended.

The drug was under review in Europe after the failure of a major study raised safety concerns.

Merck recommended that physicians stop prescribing the drug and review treatment plans for patients taking it.